Entero Therapeutics, Inc.

ENTO · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$18,059-$15,795-$14,630-$58,538
Dep. & Amort.$49$29$29$542
Deferred Tax$0$0$0$0
Stock-Based Comp.$632$1,040$769$1,371
Change in WC$2,529$2,190-$10,502$17,101
Other Non-Cash$5,632$157$277$3,463
Operating Cash Flow-$9,218-$12,378-$22,344-$32,288
Investing Activities
PP&E Inv.$0-$500$0-$10,319
Net Acquisitions$88$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0-$10
Investing Cash Flow$88-$500$0-$10,319
Financing Activities
Debt Repay.-$645-$603-$641$89
Stock Issued$6,226$15,830$23,048$32,663
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$1-$6,668$12,012
Financing Cash Flow$5,581$15,227$15,740$44,763
Forex Effect$0$0-$260$31
Net Chg. in Cash-$3,548$2,349-$6,864$2,187
Supplemental Information
Beg. Cash$3,733$1,384$8,249$6,062
End Cash$185$3,733$1,384$8,249
Free Cash Flow-$9,218-$12,878-$22,344-$42,608